Daunorubicin hydrochloride

Catalog Number : 2355061

Daunorubicin은 RNA 및 DNA 합성 억제제로서, 부분적으로 topoisomerase II의 기능을 차단하여 작용합니다.
이 물질은 급성 골수성 백혈병(acute myeloid leukemia, AML) 세포에서 세포자멸사(apoptosis)를 유도하는 것으로 보고되어 있습니다.
현재 COVID-19의 잠재적 치료제로 연구되고 있습니다.


Size	Price	제품번호
10mg	$90.00	2355061-10mg
100mg	$530.00	2355061-100mg

Download TDS

Catalog Number : 2355061

Additional Information

Applications:	FA
Synonyms:	Dauno Rubidomycine, Cerubidine, Daunoblastine, Daunorubicin, Rubidomycin, NSC 82151
Formulation:	Crystalline solid
Chemical Name:	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
Molecular Formula:	C₂₇H₂₉NO₁₀ HCl
Molecular Weight:	564.0
CAS Number	23541-50-6
Purity:	98%
Storage Conditions:	Product should be kept at -20°C.
References:	Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., … & Laurent, G. (1996). Daunorubicin‐induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. The EMBO journal, 15(10), 2417-2424. Slater, L. M., Murray, S. L., Wetzel, M. W., Wisdom, R. M., & Duvall, E. M. (1982). Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. The Journal of clinical investigation, 70(5), 1131-1134. Farag, A., Wang, P., Ahmed, M., & Sadek, H. (2020). Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning.

Daunorubicin hydrochloride ( Topoisomerase II Inhibitor ) [ 2355061 ]

본 정보는 "바이오젬스코리아"(으)로 문의 바랍니다.

연구용제품 > 바이오젬스코리아

기업정보 바로가기 >